person · Reporting owner

Daskal Ilan

Disclosed activity across 4 companies

Tapewire entity: 18506
SEC CIK: 0001446964

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
BIO-RAD LABORATORIES, INC.BIO BIOB · Entity 2247	EVP, Chief Financial Officer	September 01, 2023	September 06, 2023
VIAVI SOLUTIONS INC.VIAV · Entity 3595	EVP, CFO	September 22, 2026	September 23, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

BIO-RAD LABORATORIES, INC.

Report date September 01, 2023 · Filed September 06, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,206.212	Reported balance After 2023-09-01 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2023-09-01 · Exercise / conversion · Acquired 694 · Balance 2,206.212 F1: Shares of Class A common stock acquired on the vesting of restricted stock units. F2: Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023.
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	1,966.212	Reported balance After 2023-09-01 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2023-09-01 · Tax withholding · Disposed 240 · Balance 1,966.212
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,422.212	Reported balance After 2023-09-01 transaction · row 3 Account or security details depend on footnotes; rows are not merged. 1 source row Row 3 · 2023-09-01 · Exercise / conversion · Acquired 456 · Balance 2,422.212 F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,213.212	Reported balance After 2023-09-01 transaction · row 4 Account or security details depend on footnotes; rows are not merged. 1 source row Row 4 · 2023-09-01 · Tax withholding · Disposed 209 · Balance 2,213.212
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,755.212	Reported balance After 2023-09-02 transaction · row 5 Account or security details depend on footnotes; rows are not merged. 1 source row Row 5 · 2023-09-02 · Exercise / conversion · Acquired 542 · Balance 2,755.212 F1: Shares of Class A common stock acquired on the vesting of restricted stock units.
Bio-Rad A Common StockSEC Table I · non-derivative	Direct	2,486.212	Reported balance After 2023-09-02 transaction · row 6 Account or security details depend on footnotes; rows are not merged. 1 source row Row 6 · 2023-09-02 · Tax withholding · Disposed 269 · Balance 2,486.212
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	4,007	Reported balance After 2023-09-01 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2023-09-01 · Grant · Acquired 4,007 · Balance 4,007 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	2,082	Reported balance After 2023-09-01 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2023-09-01 · Exercise / conversion · Disposed 694 · Balance 2,082 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5: On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	912	Reported balance After 2023-09-01 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2023-09-01 · Exercise / conversion · Disposed 456 · Balance 912 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	542	Reported balance After 2023-09-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2023-09-02 · Exercise / conversion · Disposed 542 · Balance 542 F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Class A common stock acquired on the vesting of restricted stock units.

F2: Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023.

F3: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

F4: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant.

F5: On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

F6: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

F7: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

VIAVI SOLUTIONS INC.

Report date September 22, 2026 · Filed September 23, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	94,566	Ending reported balance After 2026-09-22 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2026-09-22 · Exercise / conversion · Acquired 82,671 · Balance 92,803 F1: Each stock unit converts upon vesting into one share of common stock. Row 2 · 2026-09-22 · Tax withholding · Disposed 37,285 · Balance 55,518 F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Row 3 · 2026-09-22 · Exercise / conversion · Acquired 71,127 · Balance 126,645 F1: Each stock unit converts upon vesting into one share of common stock. Row 4 · 2026-09-22 · Tax withholding · Disposed 32,079 · Balance 94,566 F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	55,115	Reported balance After 2026-09-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-09-22 · Exercise / conversion · Disposed 82,671 · Balance 55,115 F1: Each stock unit converts upon vesting into one share of common stock. F3: Shares reflect the vesting of the 2nd tranche of market-leveraged stock units granted on August 28, 2024 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement. F4: There are no expiration dates on MSUs.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	94,840	Reported balance After 2026-09-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-09-22 · Exercise / conversion · Disposed 71,127 · Balance 94,840 F1: Each stock unit converts upon vesting into one share of common stock. F5: Shares reflect the vesting of the 1st tranche of market-leveraged stock units granted on August 28, 2025 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement. F4: There are no expiration dates on MSUs.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	37,880	Reported balance After 2026-09-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-09-22 · Grant · Acquired 56,820 · Balance 37,880 F1: Each stock unit converts upon vesting into one share of common stock. F6: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2026, subject to continued service. F4: There are no expiration dates on MSUs.
Market Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	131,888	Reported balance After 2026-09-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-09-22 · Grant · Acquired 98,914 · Balance 131,888 F1: Each stock unit converts upon vesting into one share of common stock. F6: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2026, subject to continued service. F4: There are no expiration dates on MSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Each stock unit converts upon vesting into one share of common stock.

F2: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability.

F3: Shares reflect the vesting of the 2nd tranche of market-leveraged stock units granted on August 28, 2024 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement.

F4: There are no expiration dates on MSUs.

F5: Shares reflect the vesting of the 1st tranche of market-leveraged stock units granted on August 28, 2025 at 150.00% of target based on our total stockholder return during the performance periods as stated on the grant agreement.

F6: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2026, subject to continued service.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

IXIA

Report date April 18, 2017 · Filed April 20, 2017

Section 16 reporting ended · disclosed 2017-04-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2017-04-18 transaction · row 1 1 source row Row 1 · 2017-04-18 · Disposition to issuer · Disposed 16,140 · Balance 0 F1: On April 18, 2017 (the "Closing Date"), Keysight Technologies, Inc. ("Keysight") acquired the Issuer pursuant to the Agreement and Plan of Merger, dated as of January 30, 2017 (the "Merger Agreement"), by and among the Issuer, Keysight, and, by a joinder dated February 2, 2017, Keysight Acquisition, Inc., a wholly-owned subsidiary of Keysight ("Merger Sub"). On the Closing Date, in accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger (the "Merger") as a wholly owned subsidiary of Keysight. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time (other than, if any, shares owned by Keysight or Merger Sub, or by any subsidiary of Keysight, Merger Sub, or the Issuer (except to the extent held on behalf of a third party)), was automatically cancelled and converted into the right to receive $19.65 per share in cash (the "per share merger consideration"), without interest and less any applicable withholding taxes required by law. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding immediately prior to the Effective Time automatically became fully vested and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such RSU and (b) the per share merger consideration, without interest and less any applicable withholding taxes required by law. The Merger is more fully described in the Issuer's definitive proxy statement filed with the SEC on March 14, 2017. F2: Represents (i) 13,712 shares of common stock owned directly and (ii) 2,428 shares of common stock subject to unvested RSUs that were outstanding immediately prior to the Effective Time. The unvested RSUs were scheduled to vest on May 15, 2017; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the RSUs would have vested at the close of business on the business day immediately preceding the date of such Meeting.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.55 · Expires 2022-06-01	Direct	Reported balance After 2017-04-18 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2017-04-18 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F4: Option to purchase 15,000 shares vested in 4 equal quarterly installments commencing August 15, 2015.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.30 · Expires 2023-06-01	Direct	Reported balance After 2017-04-18 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2017-04-18 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law. F5: Option to purchase 15,000 shares provided for vesting in 4 equal quarterly installments commencing August 15, 2016; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the final installment would have vested at the close of business on the business day immediately preceding the date of such Meeting.

Filing footnotes · ownership attribution and instrument terms

F1: On April 18, 2017 (the "Closing Date"), Keysight Technologies, Inc. ("Keysight") acquired the Issuer pursuant to the Agreement and Plan of Merger, dated as of January 30, 2017 (the "Merger Agreement"), by and among the Issuer, Keysight, and, by a joinder dated February 2, 2017, Keysight Acquisition, Inc., a wholly-owned subsidiary of Keysight ("Merger Sub"). On the Closing Date, in accordance with the Merger Agreement, Merger Sub merged with and into the Issuer, with the Issuer surviving the merger (the "Merger") as a wholly owned subsidiary of Keysight. At the effective time of the Merger (the "Effective Time"), each share of the Issuer's common stock outstanding immediately prior to the Effective Time (other than, if any, shares owned by Keysight or Merger Sub, or by any subsidiary of Keysight, Merger Sub, or the Issuer (except to the extent held on behalf of a third party)), was automatically cancelled and converted into the right to receive $19.65 per share in cash (the "per share merger consideration"), without interest and less any applicable withholding taxes required by law. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding immediately prior to the Effective Time automatically became fully vested and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of common stock subject to such RSU and (b) the per share merger consideration, without interest and less any applicable withholding taxes required by law. The Merger is more fully described in the Issuer's definitive proxy statement filed with the SEC on March 14, 2017.

F2: Represents (i) 13,712 shares of common stock owned directly and (ii) 2,428 shares of common stock subject to unvested RSUs that were outstanding immediately prior to the Effective Time. The unvested RSUs were scheduled to vest on May 15, 2017; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the RSUs would have vested at the close of business on the business day immediately preceding the date of such Meeting.

F3: Pursuant to the Merger Agreement, at the Effective Time, each stock option that was outstanding and unexercised immediately prior to the Effective Time automatically became fully vested (to the extent not then vested) and was cancelled in consideration for the right to receive a cash payment equal to the product of (a) the total number of shares of the Issuer's common stock subject to such cancelled stock option and (b) the excess, if any, of (1) the per share merger consideration over (2) the exercise price per share of such cancelled stock option, without interest and less any applicable withholding taxes required by law.

F4: Option to purchase 15,000 shares vested in 4 equal quarterly installments commencing August 15, 2015.

F5: Option to purchase 15,000 shares provided for vesting in 4 equal quarterly installments commencing August 15, 2016; provided, however, that if the Issuer's 2017 Annual Meeting of Shareholders was held prior to May 15, 2017, the final installment would have vested at the close of business on the business day immediately preceding the date of such Meeting.

NATUS MEDICAL INC

Report date July 21, 2022 · Filed July 21, 2022

Section 16 reporting ended · disclosed 2022-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $0.001 par value per shareSEC Table I · non-derivative	Direct	0	Reported balance After 2022-07-21 transaction · row 1 1 source row Row 1 · 2022-07-21 · Disposition to issuer · Disposed 18,937 · Balance 0 F1: Disposed of pursuant to the previously announced Agreement and Plan of Merger, dated April 17, 2022, between Prince Parent Inc, Prince Mergerco Inc. and Issuer ("Merger Agreement"). F2: Each share of Common Stock was cancelled pursuant to the Merger Agreement in exchange for the right to receive the cash consideration provided in the Merger Agreement, subject to the applicable tax withholding.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the previously announced Agreement and Plan of Merger, dated April 17, 2022, between Prince Parent Inc, Prince Mergerco Inc. and Issuer ("Merger Agreement").

F2: Each share of Common Stock was cancelled pursuant to the Merger Agreement in exchange for the right to receive the cash consideration provided in the Merger Agreement, subject to the applicable tax withholding.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 28, 2024 Filed Dec 2, 2024 18:13 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	Tax withholdingCommon Stock	33,421	$9.88	$330,199.48	Disclosure SEC source: 0001127602-24-028243 · form4.xml · nonDerivative · entry 6 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,414 F2 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document
November 28, 2024 Filed Dec 2, 2024 18:13 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	Exercise / conversionCommon Stock	65,944	$0.00	$0.00	Disclosure SEC source: 0001127602-24-028243 · form4.xml · nonDerivative · entry 5 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each stock unit converts upon vesting into one share of common stock. Read SEC document
November 28, 2024 Filed Dec 2, 2024 18:13 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	Tax withholdingCommon Stock	11,581	$9.88	$114,420.28	Disclosure SEC source: 0001127602-24-028243 · form4.xml · nonDerivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,891 F2 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document
November 28, 2024 Filed Dec 2, 2024 18:13 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	Exercise / conversionCommon Stock	22,851	$0.00	$0.00	Disclosure SEC source: 0001127602-24-028243 · form4.xml · nonDerivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each stock unit converts upon vesting into one share of common stock. Read SEC document
November 28, 2024 Filed Dec 2, 2024 18:13 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	Tax withholdingCommon Stock	20,162	$9.88	$199,200.56	Disclosure SEC source: 0001127602-24-028243 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,621 F2 · shares: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the market stock award. The amount retained by the Company was not in excess of the amount of the tax liability. Read SEC document
November 28, 2024 Filed Dec 2, 2024 18:13 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	Exercise / conversionCommon Stock	39,783	$0.00	$0.00	Disclosure SEC source: 0001127602-24-028243 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,783 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each stock unit converts upon vesting into one share of common stock. Read SEC document
September 24, 2024 Filed Sep 26, 2024 18:47 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantMarket Stock Units · Derivative	22,851	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-024474 · form4.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,851 Underlying: Common Stock · 22,851 shares Expires not disclosed F1 · kind: Each stock unit converts upon vesting into one share of common stock. F2 · derivative.exercise_date: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2024, subject to continued service. F3 · derivative.expiration_date: There are no expiration dates on MSUs. Read SEC document
September 24, 2024 Filed Sep 26, 2024 18:47 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantMarket Stock Units · Derivative	39,783	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-024474 · form4.xml · derivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,783 Underlying: Common Stock · 39,783 shares Expires not disclosed F1 · kind: Each stock unit converts upon vesting into one share of common stock. F2 · derivative.exercise_date: Represents the market stock units granted on November 28, 2023, which reflect the satisfaction of performance metrics. The market stock units vest on November 28, 2024, subject to continued service. F3 · derivative.expiration_date: There are no expiration dates on MSUs. Read SEC document
August 28, 2024 Filed Aug 30, 2024 17:08 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantRestricted Stock Unit · Derivative	165,343	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-023200 · form4.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,343 Underlying: Common Stock · 165,343 shares Expires not disclosed F3 · derivative.exercise_date: Units subject to the Award shall vest annually in three equal installments F4 · derivative.expiration_date: There are no expiration dates on RSUs. Read SEC document
August 28, 2024 Filed Aug 30, 2024 17:08 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantMarket Stock Units · Derivative	165,343	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-24-023200 · form4.xml · derivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,343 Underlying: Common Stock · 165,343 shares Expires not disclosed F1 · derivative.exercise_date: See Exhibit 99 - FY25 MSU for vesting schedule and terms. F2 · derivative.expiration_date: There are no expiration dates on MSUs. Read SEC document
November 28, 2023 Filed Dec 1, 2023 00:01 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantRestricted Stock Unit · Derivative	263,774	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-23-028492 · form4.xml · derivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 263,774 shares Expires not disclosed F6 · derivative.exercise_date: Units subject to the Award shall vest annually in four equal installments F5 · derivative.expiration_date: There are no expiration dates on RSUs Read SEC document
November 28, 2023 Filed Dec 1, 2023 00:01 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantRestricted Stock Unit · Derivative	113,636	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-23-028492 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,636 shares Expires not disclosed F4 · derivative.exercise_date: Units subject to the Award shall vest annually in three equal installments F5 · derivative.expiration_date: There are no expiration dates on RSUs Read SEC document
November 28, 2023 Filed Dec 1, 2023 00:01 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantMarket Stock Units · Derivative	263,774	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-23-028492 · form4.xml · derivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 263,774 shares Expires not disclosed F3 · derivative.exercise_date: See Exhibit 99.2 - FY24 New Hire Grant MSU for vesting schedule and terms F2 · derivative.expiration_date: There are no expiration dates on MSUs Read SEC document
November 28, 2023 Filed Dec 1, 2023 00:01 UTC	VIAVI SOLUTIONS INC. VIAV · Entity 3595	GrantMarket Stock Units · Derivative	113,636	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001127602-23-028492 · form4.xml · derivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,636 shares Expires not disclosed F1 · derivative.exercise_date: See Exhibit 99.1 - FY24 Focal Grant MSU for vesting schedule and terms F2 · derivative.expiration_date: There are no expiration dates on MSUs Read SEC document
September 02, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	542	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · derivative · entry 10 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 542 Underlying: Bio-Rad A Common Stock · 542 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F7 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
September 02, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	269	$394.60	$106,147.40	Disclosure SEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 6 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,486.212 Read SEC document
September 02, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	542	$0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 5 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,755.212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	456	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · derivative · entry 9 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 912 Underlying: Bio-Rad A Common Stock · 456 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	694	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · derivative · entry 8 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,082 Underlying: Bio-Rad A Common Stock · 694 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F5 · derivative.exercise_date: On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F5 · derivative.expiration_date: On September 1, 2022, the reporting person was granted 2,776 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	GrantRestricted Stock Units · Derivative	4,007	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · derivative · entry 7 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,007 Underlying: Bio-Rad A Common Stock · 4,007 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F4 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	209	$394.60	$82,471.40	Disclosure SEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,213.212 Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	456	$0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,422.212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	240	$394.60	$94,704.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,966.212 Read SEC document
September 01, 2023 Filed Sep 6, 2023 17:00 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	694	$0.00	$0.00	Disclosure SEC source: 0001062993-23-017644 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,206.212 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 18.9440 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 06/30/2023. Read SEC document
April 08, 2023 Filed Apr 11, 2023 18:39 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	700	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-23-009008 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 700 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document
April 08, 2023 Filed Apr 11, 2023 18:39 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	243	$466.24	$113,296.32	Disclosure SEC source: 0001062993-23-009008 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,493.268 Read SEC document
April 08, 2023 Filed Apr 11, 2023 18:39 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	700	$0.00	$0.00	Disclosure SEC source: 0001062993-23-009008 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,736.268 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. F2 · balance_after: Includes 44.9320 and 38.3360 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/30/2022 and 3/31/2023, respectively. Read SEC document
September 02, 2022 Filed Sep 7, 2022 18:04 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	541	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-22-019274 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,084 Underlying: Bio-Rad A Common Stock · 541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
September 02, 2022 Filed Sep 7, 2022 18:04 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	269	$478.32	$128,668.08	Disclosure SEC source: 0001062993-22-019274 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953 Read SEC document
September 02, 2022 Filed Sep 7, 2022 18:04 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	541	$0.00	$0.00	Disclosure SEC source: 0001062993-22-019274 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,222 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 01, 2022 Filed Sep 6, 2022 17:22 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	455	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-22-019183 · form4.xml · derivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368 Underlying: Bio-Rad A Common Stock · 455 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F4 · derivative.exercise_date: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F4 · derivative.expiration_date: On September 1, 2021, the reporting person was granted 1,823 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
September 01, 2022 Filed Sep 6, 2022 17:22 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	GrantRestricted Stock Units · Derivative	2,776	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-22-019183 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,776 Underlying: Bio-Rad A Common Stock · 2,776 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document
September 01, 2022 Filed Sep 6, 2022 17:22 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	226	$486.25	$109,892.50	Disclosure SEC source: 0001062993-22-019183 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 681 Read SEC document
September 01, 2022 Filed Sep 6, 2022 17:22 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	455	$0.00	$0.00	Disclosure SEC source: 0001062993-22-019183 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 907 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
July 21, 2022 Filed Jul 21, 2022 17:14 UTC	NATUS MEDICAL INC NTUS · Entity 125256	Disposition to issuerCommon Stock, $0.001 par value per share	18,937	$33.50	$634,389.50	Disclosure SEC source: 0000878526-22-000092 · wf-form4_165843804035605.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the previously announced Agreement and Plan of Merger, dated April 17, 2022, between Prince Parent Inc, Prince Mergerco Inc. and Issuer ("Merger Agreement"). F2 · price: Each share of Common Stock was cancelled pursuant to the Merger Agreement in exchange for the right to receive the cash consideration provided in the Merger Agreement, subject to the applicable tax withholding. Read SEC document
June 15, 2022 Filed Jun 17, 2022 16:48 UTC	NATUS MEDICAL INC NTUS · Entity 125256	GrantCommon Stock, $0.001 par value per share	5,075	$0.00	$0.00	Disclosure SEC source: 0000878526-22-000041 · wf-form4_165549887372284.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,937 F1 · shares: The shares vest in full on the first anniversary of the date of the award. Read SEC document
April 08, 2022 Filed Apr 11, 2022 16:16 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	700	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-22-010014 · form4.xml · derivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,400 Underlying: Bio-Rad A Common Stock · 700 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. F3 · derivative.expiration_date: On April 8, 2019, the reporting person was granted 3,500 restricted stock units, vesting in five equal annual installments beginning on the first anniversary of the grant date. Read SEC document
April 08, 2022 Filed Apr 11, 2022 16:16 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	257	$597.16	$153,470.12	Disclosure SEC source: 0001062993-22-010014 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452 Read SEC document
April 08, 2022 Filed Apr 11, 2022 16:16 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	700	$0.00	$0.00	Disclosure SEC source: 0001062993-22-010014 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 03, 2021 Filed Sep 8, 2021 16:07 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	SaleBio-Rad A Common Stock	270	$820.06	$221,416.20	Disclosure SEC source: 0001062993-21-008354 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9 Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionRestricted Stock Units · Derivative	541	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · derivative · entry 9 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,625 Underlying: Bio-Rad A Common Stock · 541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F6 · derivative.exercise_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On September 2, 2020, the reporting person was granted 2,166 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	540	$0.00 Strike: $524.30	$0.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · derivative · entry 8 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,626 Underlying: Bio-Rad A Common Stock · 540 shares Expires 2030-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option, representing a right to purchase a total of 2,166 shares, became exercisable in four equal annual installments beginning on September 2, 2021, which was the first anniversary of the date on which the option was granted. Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Tax withholdingBio-Rad A Common Stock	269	$825.77	$222,132.13	Disclosure SEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 5 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279 Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	541	$0.00	$0.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 4 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of Class A common stock acquired on the vesting of restricted stock units. Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	SaleBio-Rad A Common Stock	100	$828.01	$82,801.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 3 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7 Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	SaleBio-Rad A Common Stock	440	$828.00	$364,320.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 2 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107 Read SEC document
September 02, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionBio-Rad A Common Stock	540	$524.30	$283,122.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · nonDerivative · entry 1 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 01, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	GrantNon-Qualified Stock Option (right to buy) · Derivative	1,823	$0.00 Strike: $814.95	$0.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · derivative · entry 7 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,823 Underlying: Bio-Rad A Common Stock · 1,823 shares Expires 2031-09-01 F4 · derivative.exercise_date: The stock option vests over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document
September 01, 2021 Filed Sep 3, 2021 21:02 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	GrantRestricted Stock Units · Derivative	1,823	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001062993-21-008242 · form4.xml · derivative · entry 6 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,823 Underlying: Bio-Rad A Common Stock · 1,823 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock. F3 · derivative.exercise_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. F3 · derivative.expiration_date: The restricted stock units vest over four years at 25% per year on the yearly anniversary date of the grant. Read SEC document
August 04, 2021 Filed Aug 5, 2021 16:38 UTC	BIO-RAD LABORATORIES, INC. BIO BIOB · Entity 2247	Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative	1,400	$0.00 Strike: $309.84	$0.00	Disclosure SEC source: 0001062993-21-007078 · form4.xml · derivative · entry 5 Daskal Ilan · CIK 0001446964 · EVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,100 Underlying: Bio-Rad A Common Stock · 1,400 shares Expires 2029-04-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option, representing a right to purchase a total of 3,500 shares, became exercisable in five equal annual installments beginning on April 8, 2020, which was the first anniversary of the date on which the option was granted. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.